Cnovas M et al
Tirzepatide is most effective when used as part of a comprehensive medical weight loss program
That includes pharmaceutical companies promoting FDA-approved medications and brands that are selling cheaper, compounded versions that are technically not FDA-approved

Canada Europe Germany UK France Spain Italy Netherlands Asia Pacific China India Japan Australia South Korea Latin America Brazil Mexico Argentina Middle East and Africa South Africa Saudi Arabia UAE Table of Contents Chapter 1 Methodology and Scope Chapter 2 Executive Summary Chapter 3 Industry Insights Chapter 4 Competitive Landscape, 2025 Chapter 5 Market Estimates and Forecast, By API, 2022 - 2035 ($ Mn) Chapter 6 Market Estimates and Forecast, By Synthesis Technology, 2022 - 2035 ($ Mn) Chapter 7 Market Estimates and Forecast, By Service Type, 2022 - 2035 ($ Mn) Chapter 8 Market Estimates and Forecast, By Scale of Operation, 2022 - 2035 ($ Mn) Chapter 9 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn) Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn) Chapter 11 Company Profiles Don't see your key competitors
Tirzepatide's dual activation may increase GI side effects, particularly during titration
Conclusions and perspectives Adequate blood supply is essential for sustaining normal bodily functions, and IRI has been shown to play a pivotal role in the onset and progression of various diseases